Alkermes (ALKS) Price & Analysis

Compare

541 Followers

ALKS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$25.56 - $36.45

Previous CloseN/A

Volume176.14K

Average Volume (3M)1.85M

Market Cap

$4.46B

Enterprise Value$4.27B

Total Cash (Recent Filing)$399.81M

Total Debt (Recent Filing)$74.10M

Price to Earnings (P/E)12.9

Beta0.85

Next Earnings

Jul 29, 2025

EPS Estimate

0.35

Last Dividend Ex-Date

Nov 16, 2023

Dividend YieldN/A

Share Statistics

EPS (TTM)0.27

Shares Outstanding164,901,290

10 Day Avg. Volume2,043,782

30 Day Avg. Volume1,854,432

Financial Highlights & Ratios

PEG Ratio-0.12

Price to Book (P/B)4.09

Price to Sales (P/S)0.00

P/FCF Ratio-248.29

Enterprise Value/Market Cap0.96

Enterprise Value/Revenue0.70

Enterprise Value/Gross Profit3.22

Enterprise Value/Ebitda2.16

Forecast

1Y Price Target

$41.50

Price Target Upside53.53% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering15

Bulls Say, Bears Say

Bulls Say

Competitive DifferentiationAlixorexton demonstrated significant improvements in wakefulness, fatigue, and cognition, which could enhance patients' quality of life and differentiate Alkermes from competitors.

Efficacy ValidationThe study helped validate ALKS2680 as an active drug in NT1 in a ~90 patient study reaching clinically meaningful and nominal stat sig on key measures of efficacy (MWT/wakefulness and Epworth sleepiness).

Safety ProfileAlixorexton is generally well-tolerated with no treatment-related safety signals observed, indicating a favorable safety profile.

Bears Say

Competitive PressureTakeda’s Ph3 trial for narcolepsy type-1 showed positive results, suggesting a high competitive bar for ALKS.

Data DisclosureThe negative stock reaction for ALKS was in response to the limited disclosure around the Ph 2b NT1 data, which led to more questions than answers.

Market ExpectationsThe success of ALKS in narcolepsy type-1 seems already priced in, indicating limited upside unless there is success in narcolepsy type-2.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

1.41% Insiders

31.30% Mutual Funds

0.47% Other Institutional Investors

36.32% Public Companies and

Individual Investors

Detailed Ownership Overview >

ALKS FAQ

What was Alkermes’s price range in the past 12 months?

Alkermes lowest stock price was $25.56 and its highest was $36.45 in the past 12 months.

What is Alkermes’s market cap?

Alkermes’s market cap is $4.46B.

When is Alkermes’s upcoming earnings report date?

Alkermes’s upcoming earnings report date is Jul 29, 2025 which is in 5 days.

How were Alkermes’s earnings last quarter?

Alkermes released its earnings results on May 01, 2025. The company reported $0.265 earnings per share for the quarter, beating the consensus estimate of $0.254 by $0.011.

Is Alkermes overvalued?

According to Wall Street analysts Alkermes’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alkermes pay dividends?

Alkermes pays a Notavailable dividend of $1.639 which represents an annual dividend yield of N/A. See more information on Alkermes dividends here

What is Alkermes’s EPS estimate?

Alkermes’s EPS estimate is 0.35.

How many shares outstanding does Alkermes have?

Alkermes has 164,901,290 shares outstanding.

What happened to Alkermes’s price movement after its last earnings report?

Alkermes reported an EPS of $0.265 in its last earnings report, beating expectations of $0.254. Following the earnings report the stock price went up 6.291%.

Which hedge fund is a major shareholder of Alkermes?

Currently, no hedge funds are holding shares in ALKS

Alkermes Stock Smart Score

Outperform

Fundamentals

Return on Equity

25.71%

Trailing 12-Months

Asset Growth

-1.97%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alkermes

Alkermes (ALKS) is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of pharmaceutical products designed to address unmet medical needs in psychiatry and addiction. The company focuses on central nervous system (CNS) disorders, including schizophrenia, bipolar disorder, and addiction, offering a portfolio of proprietary and partnered products aimed at improving patient outcomes.

ALKS Company Deck

ALKS Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a generally positive outlook with strong financial performance, significant progress in R&D, and robust commercial product growth. However, there are concerns regarding macroeconomic factors and market dependencies, which the company is actively monitoring.Read More>

ALKS Revenue Breakdown

89.69% U.S.

10.24% Rest of world

0.07% Ireland

ALKS Stock 12 Month Forecast

Average Price Target

$41.50

▲(53.53%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","55":"$55","30.25":"$30.3","38.5":"$38.5","46.75":"$46.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,30.25,38.5,46.75,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.98,30.904615384615386,32.82923076923077,34.753846153846155,36.67846153846154,38.60307692307693,40.527692307692305,42.45230769230769,44.37692307692308,46.30153846153846,48.22615384615385,50.15076923076923,52.07538461538462,{"y":54,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.98,29.943076923076923,30.906153846153845,31.869230769230768,32.832307692307694,33.79538461538461,34.75846153846154,35.72153846153846,36.684615384615384,37.64769230769231,38.61076923076923,39.573846153846155,40.536923076923074,{"y":41.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.98,29.366153846153846,29.752307692307692,30.138461538461538,30.524615384615384,30.91076923076923,31.29692307692308,31.683076923076925,32.06923076923077,32.45538461538462,32.84153846153846,33.22769230769231,33.613846153846154,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.4,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.39,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.83,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.76,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.53,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.98,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >